1. Home
  2. Studies
  3. CDT : Clinical Studies (index)
scientific and microscope

Our clinical studies

We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.

 

Clinical studies

This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.
 

Total studies

0

Current studies

0

Oncology

0

Dermatology

0

Rare diseases

0

Others

0
Show more filters
Title Therapeutic area Phase Status Start date (Planned) End date

Multicenter, Open-label, Phase II Study with a Safety Lead-in part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAFV600E mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer who are BRAF- and MEK inhibitor treatment-naïve

 		Oncology Phase II Recruiting 02 June 2022 February 2025

A prospective non interventional study on targeted therapy for patients with unresectable or metastatic BRAFV600E mutant melanoma (TAVIE-Skin)

 		Oncology RWE Recruiting February 2021 December 2024

A multicenter, randomized, open-label, 2-arm, Phase II trial with a safety lead-in phase evaluating the combination of encorafenib and cetuximab versus irinotecan/cetuximab or infusional 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI)/cetuximab in Chinese patients with BRAFV600E mutant metastatic colorectal cancer.

 		Oncology Phase II Recruiting 02 September 2021 September 2024

Phase I dose escalation and dose expansion, international, multicenter study of W0180 as single agent and in combination with pembrolizumab (anti-PD-1) in adult participants with locally advanced or metastatic solid tumors.

 		Oncology Phase I Recruiting 08 September 2020 May 2024

A 6-months prospective, observational study to evaluate the quality of life of patients treated with phytotherapy or alpha-blockers for benign prostatic hyperplasia.

 		Urology RWE Active June 2022 February 2024
6 - 10 over 126

Get access to Partner's pivotal studies supporting our authorized drugs in Europe

Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below:

 

Melanoma

Phase III  -  COLUMBUS

SPONSOR: PFIZER

Breast cancer 

Phase III    -    EXTENET

SPONSOR: PUMA BIOTECHNOLOGY

Colorectal cancer

Phase III - BEACON CRC

SPONSOR: PFIZER

Post-transplantation lymphoproliferative disease EBV+

Phase III     -       ALLELE

SPONSOR: ATARA

 

 

 

 

Studies status

Lorem ipsum dolor

Sed hendrerit lorem augue, at molestie ligula dapibus id. Phasellus eu ullamcorper diam.

Lorem ipsum dolor

Sed at augue ut ex tempor congue convallis sed orci. Suspendisse congue pellentesque velit non convallis. Integer nec risus eu urna finibus ornare nec nec eros.

Lorem ipsum dolor

Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Nulla dapibus id dolor placerat gravida.

Lorem ipsum dolor

Integer vel tortor sapien. Nulla elit tellus, interdum vitae lobortis id, scelerisque nec elit. Donec ut maximus nibh. Nunc sit amet nibh nec leo scelerisque tempus id sed nisi. Duis vehicula sem sit amet elit cursus, nec ultrices turpis cursus.

Lorem ipsum dolor

Donec eget ultrices justo. Donec posuere, nibh quis dignissim feugiat, ante turpis pharetra sapien, vel faucibus magna leo eu quam. Fusce sed massa sapien.

Lorem ipsum dolor

Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Nulla dapibus id dolor placerat gravida.

Lorem ipsum dolor

Nunc congue diam metus, id hendrerit nulla fringilla non. Nullam non interdum dui. Phasellus quis dapibus erat. Aliquam metus ipsum, luctus nec mollis vitae, varius ut massa.